Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 6/2009

01-05-2009 | Original Article

Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients

Authors: Jürgen B. Bulitta, Ping Zhao, Robert D. Arnold, Dean R. Kessler, Richard Daifuku, James Pratt, Gabriel Luciano, Axel-R Hanauske, Hans Gelderblom, Ahmad Awada, William J. Jusko

Published in: Cancer Chemotherapy and Pharmacology | Issue 6/2009

Login to get access

Abstract

Purpose

Our objectives were (1) to compare the disposition and in vivo release of paclitaxel between a tocopherol-based Cremophor-free formulation (Tocosol Paclitaxel®) and Cremophor® EL-formulated paclitaxel (Taxol®) in human subjects, and (2) to develop a mechanistic model for unbound and total paclitaxel pharmacokinetics.

Methods

A total of 35 patients (average ± SD age: 59 ±13 years) with advanced non-hematological malignancies were studied in a randomized two-way crossover trial. Patients received 175 mg/m2 paclitaxel as 15 min (Tocosol Paclitaxel) or 3 h (Taxol) intravenous infusion in each study period. Paclitaxel concentrations were determined by LC–MS/MS in plasma ultrafiltrate and whole blood. NONMEM VI was used for population pharmacokinetics.

Results

A linear disposition model with three compartments for unbound paclitaxel and a one-compartment model for Cremophor were applied. Total clearance of unbound paclitaxel was 845 L/h (variability: 25% CV). The prolonged release with Tocosol Paclitaxel was explained by the limited solubility of unbound paclitaxel of 405 ng/mL (estimated) in plasma. The 15 min Tocosol Paclitaxel infusion yielded a mean time to 90% cumulative input of 1.14 ± 0.16 h. Tocosol Paclitaxel was estimated to release 9.8% of the dose directly into the deep peripheral compartment. The model accounted for the presence of drug-containing nanodroplets in blood.

Conclusions

Population pharmacokinetic analysis indicated linear disposition and a potentially higher bioavailability of unbound paclitaxel following Tocosol Paclitaxel administration due to direct release at the target site. The prolonged release of Tocosol Paclitaxel supports 15 min paclitaxel infusions. This mechanistic model may be important for development of prolonged release formulations that distribute in and from the systemic circulation.
Appendix
Available only for authorised users
Literature
1.
Beal SL, Sheiner LB, Boeckmann AJ (2006) NONMEM Users Guides (1989–2006). Icon Development Solutions, Ellicott City
2.
Brat DJ, Windebank AJ, Brimijoin S (1992) Emulsifier for intravenous cyclosporin inhibits neurite outgrowth, causes deficits in rapid axonal transport and leads to structural abnormalities in differentiating N1E.115 neuroblastoma. J Pharmacol Exp Ther 261:803–810PubMed
3.
Brouwer E, Verweij J, De Bruijn P, Loos WJ, Pillay M, Buijs D, Sparreboom A (2000) Measurement of fraction unbound paclitaxel in human plasma. Drug Metab Dispos 28:1141–1145PubMed
4.
Brown T, Havlin K, Weiss G, Cagnola J, Koeller J, Kuhn J, Rizzo J, Craig J, Phillips J, Von Hoff D (1991) A phase I trial of taxol given by a 6-hour intravenous infusion. J Clin Oncol 9:1261–1267PubMed
5.
Constantinides PP, Lambert KJ, Tustian AK, Schneider B, Lalji S, Ma W, Wentzel B, Kessler D, Worah D, Quay SC (2000) Formulation development and antitumor activity of a filter-sterilizable emulsion of paclitaxel. Pharm Res 17:175–182PubMedCrossRef
6.
Constantinides PP, Tustian A, Kessler DR (2004) Tocol emulsions for drug solubilization and parenteral delivery. Adv Drug Deliv Rev 56:1243–1255PubMedCrossRef
7.
Dhanikula AB, Panchagnula R, Singh I, Kaur KJ, Kaul CL, Sekhon JS (2001) Pharmacokinetic study of paclitaxel as a 3-hour infusion in an Indian population: 135 mg/m2 vs. 175 mg/m2. Methods Find Exp Clin Pharmacol 23:93–98PubMedCrossRef
8.
Dorr RT (1994) Pharmacology and toxicology of Cremophor EL diluent. Ann Pharmacother 28:S11–S14PubMed
9.
Gelderblom H, Mross K, ten Tije AJ, Behringer D, Mielke S, van Zomeren DM, Verweij J, Sparreboom A (2002) Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions. J Clin Oncol 20:574–581PubMedCrossRef
10.
Gelderblom H, Verweij J, Brouwer E, Pillay M, de Bruijn P, Nooter K, Stoter G, Sparreboom A (1999) Disposition of [G-(3)H]paclitaxel and cremophor EL in a patient with severely impaired renal function. Drug Metab Dispos 27:1300–1305PubMed
11.
Gianni L, Kearns CM, Giani A, Capri G, Vigano L, Lacatelli A, Bonadonna G, Egorin MJ (1995) Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 13:180–190PubMed
12.
Hamada H, Ishihara K, Masuoka N, Mikuni K, Nakajima N (2006) Enhancement of water-solubility and bioactivity of paclitaxel using modified cyclodextrins. J Biosci Bioeng 102:369–371PubMedCrossRef
13.
Hempel G, Rube C, Mosler C, Wienstroer M, Wagner-Bohn A, Schuck A, Willich N, Boos J (2003) Population pharmacokinetics of low-dose paclitaxel in patients with brain tumors. Anticancer Drugs 14:417–422PubMedCrossRef
14.
Henningsson A, Karlsson MO, Vigano L, Gianni L, Verweij J, Sparreboom A (2001) Mechanism-based pharmacokinetic model for paclitaxel. J Clin Oncol 19:4065–4073PubMed
15.
Henningsson A, Marsh S, Loos WJ, Karlsson MO, Garsa A, Mross K, Mielke S, Vigano L, Locatelli A, Verweij J, Sparreboom A, McLeod HL (2005) Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res 11:8097–8104PubMedCrossRef
16.
Henningsson A, Sparreboom A, Sandstrom M, Freijs A, Larsson R, Bergh J, Nygren P, Karlsson MO (2003) Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients. Eur J Cancer 39:1105–1114PubMedCrossRef
17.
Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E, Esmaeli B, Ring SE, Bedikian A, Hortobagyi GN, Ellerhorst JA (2002) Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 8:1038–1044PubMed
18.
Joerger M, Huitema AD, van den Bongard DH, Schellens JH, Beijnen JH (2006) Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of Paclitaxel in patients with solid tumors. Clin Cancer Res 12:2150–2157PubMedCrossRef
19.
Karlsson MO, Molnar V, Freijs A, Nygren P, Bergh J, Larsson R (1999) Pharmacokinetic models for the saturable distribution of paclitaxel. Drug Metab Dispos 27:1220–1223PubMed
20.
Kearns CM, Gianni L, Egorin MJ (1995) Paclitaxel pharmacokinetics and pharmacodynamics. Semin Oncol 22:16–23PubMed
21.
Kessel D (1992) Properties of cremophor EL micelles probed by fluorescence. Photochem Photobiol 56:447–451PubMedCrossRef
22.
Kumar GN, Walle UK, Bhalla KN, Walle T (1993) Binding of taxol to human plasma, albumin and alpha 1-acid glycoprotein. Res Commun Chem Pathol Pharmacol 80:337–344PubMed
23.
Monsarrat B, Alvinerie P, Wright M, Dubois J, Gueritte-Voegelein F, Guenard D, Donehower RC, Rowinsky EK (1993) Hepatic metabolism and biliary excretion of Taxol in rats and humans. J Natl Cancer Inst Monogr 15:39–46PubMed
24.
Mosteller RD (1987) Simplified calculation of body-surface area. N Engl J Med 317:1098PubMed
25.
Mould DR, Fleming GF, Darcy KM, Spriggs D (2006) Population analysis of a 24-h paclitaxel infusion in advanced endometrial cancer: a gynaecological oncology group study. Br J Clin Pharmacol 62:56–70PubMedCrossRef
26.
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655PubMedCrossRef
27.
Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC (1993) Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 20:1–15PubMed
28.
Sapra P, Tyagi P, Allen TM (2005) Ligand-targeted liposomes for cancer treatment. Curr Drug Deliv 2:369–381PubMedCrossRef
29.
Sharma US, Balasubramanian SV, Straubinger RM (1995) Pharmaceutical and physical properties of paclitaxel (Taxol) complexes with cyclodextrins. J Pharm Sci 84:1223–1230PubMedCrossRef
30.
Sonnichsen DS, Hurwitz CA, Pratt CB, Shuster JJ, Relling MV (1994) Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. J Clin Oncol 12:532–538PubMed
31.
Sparreboom A, Loos WJ, Verweij J, de Vos AI, van der Burg ME, Stoter G, Nooter K (1998) Quantitation of Cremophor EL in human plasma samples using a colorimetric dye-binding microassay. Anal Biochem 255:171–175PubMedCrossRef
32.
Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH (1996) Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res 56:2112–2115PubMed
33.
Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH (1996) Tissue distribution, metabolism and excretion of paclitaxel in mice. Anticancer Drugs 7:78–86PubMedCrossRef
34.
Sparreboom A, van Zuylen L, Brouwer E, Loos WJ, de Bruijn P, Gelderblom H, Pillay M, Nooter K, Stoter G, Verweij J (1999) Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 59:1454–1457PubMed
35.
Sparreboom A, Verweij J, van der Burg ME, Loos WJ, Brouwer E, Vigano L, Locatelli A, de Vos AI, Nooter K, Stoter G, Gianni L (1998) Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo. Clin Cancer Res 4:1937–1942PubMed
36.
Spigel SC, Jones SF, Greco FA (2002) S-8184 vitamin E paclitaxel emulsion: preclinical and phase 1 data. Proc Am Soc Clin Oncol 21. Abstract no. 406
37.
Straubinger RM, Balasubramanian SV (2005) Preparation and characterization of taxane-containing liposomes. Methods Enzymol 391:97–117PubMedCrossRef
38.
van den Bongard HJ, Mathot RA, van Tellingen O, Schellens JH, Beijnen JH (2002) A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling. Cancer Chemother Pharmacol 50:16–24PubMedCrossRef
39.
van Tellingen O, Beijnen JH, Verweij J, Scherrenburg EJ, Nooijen WJ, Sparreboom A (1999) Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice. Clin Cancer Res 5:2918–2924PubMed
40.
van Tellingen O, Huizing MT, Panday VR, Schellens JH, Nooijen WJ, Beijnen JH (1999) Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. Br J Cancer 81:330–335PubMedCrossRef
41.
van Zuylen L, Karlsson MO, Verweij J, Brouwer E, de Bruijn P, Nooter K, Stoter G, Sparreboom A (2001) Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles. Cancer Chemother Pharmacol 47:309–318PubMedCrossRef
42.
van Zuylen L, Verweij J, Sparreboom A (2001) Role of formulation vehicles in taxane pharmacology. Invest New Drugs 19:125–141PubMedCrossRef
43.
Walle T, Walle UK, Kumar GN, Bhalla KN (1995) Taxol metabolism and disposition in cancer patients. Drug Metab Dispos 23:506–512PubMed
44.
Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, Baker JR Jr, Van Echo DA, Von Hoff DD, Leyland-Jones B (1990) Hypersensitivity reactions from taxol. J Clin Oncol 8:1263–1268PubMed
45.
Wiernik PH, Schwartz EL, Einzig A, Strauman JJ, Lipton RB, Dutcher JP (1987) Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J Clin Oncol 5:1232–1239PubMed
46.
Wild MD, Walle UK, Walle T (1995) Extensive and saturable accumulation of paclitaxel by the human platelet. Cancer Chemother Pharmacol 36:41–44PubMedCrossRef
47.
Windebank AJ, Blexrud MD, de Groen PC (1994) Potential neurotoxicity of the solvent vehicle for cyclosporine. J Pharmacol Exp Ther 268:1051–1056PubMed
Metadata
Title
Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients
Authors
Jürgen B. Bulitta
Ping Zhao
Robert D. Arnold
Dean R. Kessler
Richard Daifuku
James Pratt
Gabriel Luciano
Axel-R Hanauske
Hans Gelderblom
Ahmad Awada
William J. Jusko
Publication date
01-05-2009
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 6/2009
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-008-0827-2

Other articles of this Issue 6/2009

Cancer Chemotherapy and Pharmacology 6/2009 Go to the issue

Short Communication

Early severe toxicities after capecitabine intake: possible implication of a cytidine deaminase extensive metabolizer profile

Original Article

Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer

Original Article

Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature

Original Article

Studies of structure–activity relationship on plant polyphenol-induced suppression of human liver cancer cells

Short Communication

Isolated molecular relapse in FIP1L1-PDGFRα hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose

Short Communication

Life-threatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits